CA
NZ
UK
AU
IND
US
…
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company's technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information about Autonomix Medical, Inc. (NASDAQ: AMIX) is limited and filings provide few details on products, operations, or revenues. Long-term growth could depend on regulatory approvals, successful commercialization, strategic partnerships, and access to capital, which may support scaling and adoption.
Key risks are high execution and financing risk tied to limited disclosure, potential regulatory and clinical setbacks, low liquidity and share-price volatility.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Income before tax | -11.41M | -15.43M | -1.99M | -13.33M |
| Net income | -11.41M | -15.43M | -1.99M | -13.33M |
| Selling general administrative | 6.86M | 5.25M | 1.25M | 13.59M |
| Selling and marketing expenses | - | 0.08M | 0.09M | - |
| Gross profit | -0.18M | -0.08M | - | - |
| Reconciled depreciation | 0.18M | 0.08M | 0.00M | - |
| Ebit | -11.23M | -15.35M | -3.98M | -12.84M |
| Ebitda | -11.05M | -15.27M | -1.99M | 0.75M |
| Depreciation and amortization | 0.18M | 0.08M | 1.99M | 13.59M |
| Operating income | -11.59M | -7.47M | -1.99M | -13.59M |
| Other operating expenses | 11.59M | 7.47M | 1.99M | 13.59M |
| Interest expense | 0.18M | 0.08M | 0.00M | 0.22M |
| Tax provision | 0.00M | 0.00M | 0.00M | - |
| Interest income | 0.35M | 0.13M | 0.00M | - |
| Net interest income | 0.18M | 0.05M | 0.00M | - |
| Income tax expense | - | - | -1.99M | -13.59M |
| Total revenue | 0.00M | 0.00M | 0.00M | - |
| Total operating expenses | 11.59M | 7.47M | 1.99M | 13.59M |
| Cost of revenue | 0.18M | 0.08M | - | - |
| Total other income expense net | 0.18M | -7.95M | 0.00M | 0.27M |
| Net income from continuing ops | -11.41M | -15.43M | -1.99M | - |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Total assets | 9.81M | 9.41M | 0.86M | 2.05M |
| Other current assets | 0.47M | 0.78M | - | 0.01M |
| Total liab | 1.71M | 1.78M | 0.22M | 0.09M |
| Total stockholder equity | 8.10M | 7.63M | 0.64M | 1.96M |
| Other current liab | 1.03M | 0.28M | 0.05M | 0.00M |
| Common stock | 0.00M | 0.02M | 0.01M | 0.01M |
| Capital stock | 0.00M | 0.02M | 0.01M | - |
| Retained earnings | -50.38M | -38.97M | -23.54M | -21.55M |
| Cash | 9.14M | 8.61M | 0.86M | 2.04M |
| Total current liabilities | 1.71M | 0.78M | 0.22M | 0.09M |
| Net debt | -9.14M | -7.61M | -0.86M | -2.04M |
| Short long term debt total | - | 1.00M | - | - |
| Other stockholder equity | 58.48M | 46.58M | 24.18M | 23.50M |
| Total current assets | 9.61M | 9.39M | 0.86M | 2.05M |
| Long term debt | - | 1.00M | - | - |
| Accounts payable | 0.68M | 0.49M | 0.17M | 0.09M |
| Non currrent assets other | 0.18M | - | - | - |
| Non current assets total | 0.20M | 0.02M | 0.00M | - |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Investments | -0.01M | -0.02M | 0.00M | - |
| Total cashflows from investing activities | -0.01M | - | - | - |
| Net borrowings | 0.00M | - | - | - |
| Total cash from financing activities | 8.80M | 14.41M | 0.68M | 2.43M |
| Net income | -11.41M | -15.43M | -1.99M | -13.33M |
| Change in cash | 0.53M | 7.74M | -1.18M | 2.04M |
| Begin period cash flow | 8.61M | 0.86M | 2.04M | 0.00M |
| End period cash flow | 9.14M | 8.61M | 0.86M | 2.04M |
| Total cash from operating activities | -8.26M | -6.65M | -1.85M | -0.39M |
| Issuance of capital stock | 10.03M | 13.71M | 0.68M | - |
| Depreciation | 0.18M | 0.08M | 0.00M | - |
| Other cashflows from financing activities | -1.23M | -1.30M | 0.00M | 0.00M |
| Capital expenditures | 0.01M | 0.02M | 0.00M | 0.00M |
| Change in working capital | 1.24M | 0.08M | 0.14M | 0.20M |
| Stock based compensation | 1.63M | 0.00M | 0.00M | 0.00M |
| Other non cash items | 0.10M | 8.62M | -0.08M | 12.65M |
| Free cash flow | -8.27M | -6.67M | -1.85M | -0.39M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| AMIX Autonomix Medical, Inc. Common Stock |
0.08 3.86% |
2.15 | - | - | - | 0.53 |
| ABT Abbott Laboratories |
-0.46 0.45% |
102.64 | 25.97 | 17.24 | 3.57 | 3.20 |
| MDT Medtronic PLC |
0.83 0.88% |
94.78 | 26.60 | 15.87 | 3.35 | 2.08 |
| SYK Stryker Corporation |
2.58 0.86% |
304.00 | 29.23 | 16.86 | 4.18 | 4.51 |
| SEMHF Siemens Healthineers AG |
- -% |
47.39 | 39.57 | 21.32 | 3.01 | 3.29 |
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company's technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
| Name | Title | Year Born |
|---|---|---|
| Mr. Walter V. Klemp | Executive Chairman | 1960 |
| Dr. Robert Schwartz M.D. | Co-Founder & Chief Medical Officer | 1952 |
| Mr. Landy Toth | Co-Founder & Chief Technology Officer | 1978 |
| Ms. Lori H. Bisson | CEO & Director | 1972 |
| Mr. Trent N. Smith CPA | Chief Financial Officer | 1969 |
| Ms. Jennifer Cook | Chief Business Officer | NA |
| Ms. Lori H. Bisson | Executive Vice Chairman | 1971 |
| Dr. Robert Schwartz M.D. | Co-Founder & Chief Medical Officer | 1951 |
| Mr. Landy Toth | Co-Founder & Chief Technology Officer | 1977 |
| Mr. Bradley Hauser | CEO & President | 1977 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.02%
Communication Services
-0.63%
Consumer Cyclical
-0.11%
Consumer Defensive
-0.45%
Energy
+0.39%
Financial Services
-0.10%
Financials
-0.81%
Healthcare
+1.03%
Industrials
+0.32%
Real Estate
-0.31%
Technology
+0.59%
Utilities
-0.18%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...